Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Payables (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Payables data on record, last reported at $3.0 million in Q4 2025.

  • For Q4 2025, Payables rose 32.01% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, up 32.01%, while the annual FY2025 figure was $3.0 million, 32.01% up from the prior year.
  • Payables reached $3.0 million in Q4 2025 per TLSI's latest filing, down from $3.8 million in the prior quarter.
  • Across five years, Payables topped out at $5.9 million in Q4 2022 and bottomed at $1.4 million in Q3 2024.
  • Average Payables over 4 years is $2.7 million, with a median of $2.3 million recorded in 2024.
  • Peak YoY movement for Payables: tumbled 53.43% in 2024, then skyrocketed 161.69% in 2025.
  • A 4-year view of Payables shows it stood at $5.9 million in 2022, then plummeted by 42.44% to $3.4 million in 2023, then plummeted by 32.94% to $2.3 million in 2024, then skyrocketed by 32.01% to $3.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $3.0 million in Q4 2025, $3.8 million in Q3 2025, and $1.9 million in Q2 2025.